Title: Navidea Biopharmaceuticals Files Form 15, Streamlining Reporting Obligations for Strategic Focus

Navidea Biopharmaceuticals, Inc. takes steps to optimize resources and focus on core business.

---

In an effort to streamline reporting obligations and align with its strategic focus, Navidea Biopharmaceuticals, Inc. has filed a Form 15 with the Securities and Exchange Commission (SEC) to deregister its common stock and suspend its reporting obligations. This move comes as the company aims to reduce complexity and costs following its recent delisting from the NYSE American.

By voluntarily deregistering, Navidea Biopharmaceuticals will no longer be a public reporting company and will no longer be required to file periodic reports with the SEC. This decision will enable the management team to concentrate their efforts on the company's core business activities and further enhance their [Fix, Fund, Propel](https://www.navidea.com/news-media/press-releases/detail/434/navidea-biopharmaceuticals-inc-drives-strategy-forward) approach.

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Its primary objective is to improve patient care by identifying disease sites and pathways, leading to better diagnostic accuracy, clinical decision-making, and targeted treatment. The company's Manocept platform, which targets the CD206 mannose receptor expressed on activated macrophages, forms the basis of its precision-targeted products.

One of the key products developed and commercialized by Navidea is Tc99m tilmanocept, which serves as a molecular backbone for the Manocept platform. Moving forward, the company aims to bring novel products to market and advance its pipeline through global partnering and commercialization efforts.

Navidea Biopharmaceuticals' decision to deregister and suspend reporting obligations is expected to have no impact on its business operations. Instead, it is a strategic move aimed at optimizing resources and focusing on core business activities. By eliminating the need for continuous SEC reporting, the company can allocate resources more effectively to drive its growth and enhance shareholder value.

As a biopharmaceutical company, Navidea Biopharmaceuticals operates in a highly dynamic industry. Developing precision immunodiagnostic agents and immunotherapeutics requires extensive research, development, and regulatory compliance. By eliminating the burden of regular reporting, the company can allocate resources to these critical areas, ensuring that it remains at the forefront of innovation.

It's important to note that deregistering and suspending reporting obligations does not mean that Navidea Biopharmaceuticals is exempt from financial scrutiny or regulatory compliance. The company will continue to comply with all applicable laws and regulations, ensuring transparency and accountability.

The decision to deregister and suspend reporting obligations is an essential step for Navidea Biopharmaceuticals as it aligns its operations with its strategic focus. By optimizing resources and streamlining reporting, the company can enhance its agility and respond more effectively to industry trends and market dynamics.

Navidea Biopharmaceuticals' strategic approach of Fix, Fund, Propel will now be further strengthened with this move. The company can concentrate on its core competencies, driving innovation, and delivering superior growth. By bringing novel products to market and advancing its pipeline, Navidea Biopharmaceuticals aims to provide healthcare solutions that improve patient outcomes and revolutionize the field of precision medicine.

In conclusion, Navidea Biopharmaceuticals' decision to voluntarily deregister and suspend reporting obligations is a strategic move that optimizes resources and enables the company to focus on its core business activities. By streamlining reporting obligations, Navidea Biopharmaceuticals can allocate resources more effectively, driving growth, and enhancing shareholder value. As the company continues to develop precision immunodiagnostic agents and immunotherapeutics, its commitment to innovation and patient care remains unwavering.